双黄连：“肺炎神药”的生意经与隐秘往事。
Shuang Huanglian: The Business History and Secret History of "Pneumonia".
放大灯团队。
Enlarge the light team.
放大灯                      。
Amplify the lights.
放大灯。
Amplify the lights.
果壳旗下科技产业新媒体。
Fruit shell technology industry new media.
我们聚焦与新科技有关的技术、公司、产业和社会人物报道，做“从实验室到产业市场”的报道者、观察者和学习者。
We focus on technology, companies, industries, and social figures reporting on new technologies, as reporters, observers, and learners "from the laboratory to the industrial market."
。
.
春节过后，新冠肺炎正继续表现出令人不快的一面：疫情阴影下的股市呈现冰火两重天的奇景：那边厢是开市首日近三千只个股跌停，这边厢则是医药公司股价高歌猛进纷纷涨停。
After the Spring Festival, the new crown pneumonia is continuing to take on an unpleasant aspect: the stock market in the shadow of the epidemic is showing a double-edged spectacle: the side box where nearly 3,000 shares are trading on the first day of trading, and where pharmaceutical companies are soaring.
疫苗、口罩等概念股的涨势尽在情理中，这一轮汹涌行情背后还有一股毫不意外的助推剂——“双黄连”。
Vaccines, masks and other conceptual stocks rose in the reasonable, this round of turbulent market behind a not unexpected booster - "Shuanghuanglian."
策划丨放大灯团队（ID：guokr233）作者丨一萌、普通酱编辑丨一萌题图丨Pixabay吹起双黄连的泡沫1月31日，《人民日报》披露称：武汉病毒所与中科院上海药物的研究团队通过实验室体外试验证明，双黄连有抑制新型冠状病毒作用，下一步还需通过进一步临床研究来证实。
The Wuhan Virus Institute and the Shanghai pharmaceutical research team of the Chinese Academy of Sciences have demonstrated in vitro that Shuang Huanglian acts as a inhibitor to the new coronavirus, and further clinical research is needed to confirm it, the People's Daily said on January 31.
若论带货能力，还得看它消息引发的全国范围抢购风潮，直接导致双黄连线上线下瞬间断货。
If the ability to carry goods, but also to see its news triggered a nationwide rush to buy, directly leading to Shuanghuanglian online instantaneous offline.
双黄连及其研究机构，武汉病毒所与上海药物研究所，均遭科研与医疗工作者猛烈批评，但这些都不妨碍两天后市场疯狂追捧双黄连。
Shuang Huanglian and his research institute, Wuhan Virus Institute and Shanghai Pharmaceutical Research Institute, were heavily criticized by researchers and medical workers, but none of this prevented the market from frantically pursuing Shuanghuanglian two days later.
放大灯团队（ID：guokr233）注意到：2月3日和4日，“双黄连概念股”哈药股份、太龙药业一字涨停。
Enlarged lamp team (ID: guokr233) notice: Feb. 3 and 4, "Shuanghuanglian concept shares" Ha medicine shares, Tai Long pharmaceutical industry a word limit.
港股福森药业，3日当天股价涨幅一度高达230%，收盘涨幅也达到41.11%。
Hong Kong-based Fujimori Pharmaceutical shares rose 230% on the day, closing up 41.11%.
这些公司股价凭什么疯涨？位居国内药企前列的恒瑞医药，2月3日的动态市盈率为75.9倍，相比之下，太龙药业、福森药业当天动态市盈率都达到80倍左右，哈药股份动态市盈率则达到惊人的1969.90倍。
Hang Seng, the leading Chinese pharmaceutical company, traded at 75.9 times the dynamic price / earnings ratio on February 3, compared with around 80 times for Tai Long and 80 times for Forson and a staggering 196. 90 times for Haji shares.
泡沫凶猛。
The bubble is fierce.
市盈率只是一个比较简单粗暴的衡量标准。
The P / E ratio is just a rough measure.
药从关外来什么是双黄连？它有什么特殊之处？它从哪里来？又经历了怎样的发展轨迹？双黄连由金银花（双花）、黄芩和连翘三味中药配伍而成，化裁自清代温病学家吴瑭《温病条辨》的“银翘散”。
What is Shuanghuanglian from outside the customs? What is special about it? Where does it come from? What is its development trajectory? Shuanghuanglian is composed of Honeysuckle (Double Flower), Scutellaria baicalensis and Forsythia.
双黄连的历史并不算悠久，但在现有的网络信息中，也无法准确地指出究竟是何人、何时开发出这个如今家喻户晓的方子。
Shuanghuanglian history is not very long, but in the existing network information, can not precisely point out who, when the development of this now well-known formula.
有文献可考的历史表明，双黄连方剂产生于文革期间的东北地区——再准确一点，黑龙江哈尔滨，并且与现在的哈药集团有着千丝万缕的联系。
There is a documented history that Shuanghuanglian Formula originated in the Northeast during the Cultural Revolution - or, to be more precise, Harbin in Heilongjiang, and is inextricably linked to today's pharmaceutical group.
在另外一篇河南太龙（双黄连口服液的主要生产厂家之一）宣传文稿中介绍，双黄连汤剂起源于战争时期，后来，为解决药品缺乏，制成注射液并在文革期间被巡回医疗队广泛应用于下乡临床。
Shuanghuanglian decoction originated during the war and was later developed into an injection and widely used by mobile medical teams in rural areas during the Cultural Revolution to address the shortage of medicines.
20世纪70年代初，哈尔滨医科大学二附院从三味中药中提取制成无菌粉针剂[1]。
At the beginning of the 1970s, Harbin Medical University Hospital No. 2 was made from Sanwei TCM to make aseptic powder & # 91; 1 & # 93;
1976年5月，在黑龙江举行“中草药交流现场会”上，鹤岗市推广了使用双黄连注射液治疗小儿肺炎的尝试[2]。
In May 1976, Hegang City promoted the use of Shuanghuanglian injection to treat pediatric pneumonia at a "herbal exchange site" in Heilongjiang.
此后30年，双黄连与黑龙江乃至东北地区的关系甚深。
For the next 30 years, Shuang Huanglian had a deep relationship with Heilongjiang and Northeast China.
在中国知网数据库中查询“双黄连“，可以发现，自1977年起，在长达15年的时间里，几乎所有论文——包括兽医兽药论文——都出自黑龙江省的科研与生产机构。
A search for Shuanghuang Lianlian in China's online database shows that, since 1977, almost all papers - including veterinary veterinary papers - have come from research and production facilities in Heilongjiang Province.
其中最早期的论文，正是将双黄连注射剂用于治疗小儿肺炎的临床论文（时过境迁，双黄连以及其它几个常用的中成药注射液，已被禁止用于婴幼儿）。
One of the earliest papers was a clinical paper on the use of Shuanghuanglian injection in the treatment of pediatric pneumonia (Shuanghuanglian and several other commonly used Chinese patent medicine injection have been banned for infants and children).
1977~1992年，绝大部分“双黄连”主题的论文出自黑龙江地区，制表丨放大灯团队值得注意的是，上海药物研究所与武汉病毒所的“抗病毒研究”也不是首创，早在20世纪80年代末，双黄连注射液对抗病毒的实验就已有论文发布，其中一篇题为《双黄连口服液抗呼吸道合胞病毒的实验研究》论文[3]，被钟南山院士在2005年前后的两篇论文中被引用[4][5]。
From 1977 to 1992, the vast majority of papers on the subject came from Heilongjiang. The Shanghai Institute of Medicine and Wuhan Virus Research Group are notable for their antiviral research. As early as the late 1980s, Shuanghuanglian Injection had published a paper entitled "Experimental Study of Shuanghuanglian Oral Liquid against Respiratory Syncytial Virus."
另外，关于双黄连注射液引发过敏反应的论文，也早在1991年就有简短报道[6]——“但笔者在所查阅的资料中还未发现有关双黄连注射液出现过敏反应之事，故报道出来以引起同仁的注意。
At the same time, a brief report on the allergic reaction of Shuanghuanglian injection was provided as early as 1991. "But the information I have reviewed does not reveal any allergic reaction to Shuanghuanglian Injection, and is reported to have attracted colleagues' attention.
”双黄连是什么时候走出东北、走向全国的？1992年，一个特别的年份。
When did Shuang Huanglian leave the Northeast and go nationwide? In 1992, it was a special year.
在这一年，首批外省的双黄连临床病例论文发布，这些论文出自山东、安徽等地的医院，采用哈尔滨中药二厂生产的“双黄连粉针剂“，进行了上百例临床应用。
During the year, the first clinical case papers of Shuanghuanglian from Shandong, Anhui and other hospitals were published, using "Shuanghuanglian Powder" produced by the second factory of Chinese medicine in Harbin, with hundreds of clinical applications.
双黄连走出山海关，可能的原因，一方面是因为生产问题得到了解决——在九十年代初的论文中，两个关键的产品批号在多篇论文中出现：由黑龙江省药品检验所制造的，批号为890324的双黄连口服液，以及由哈尔滨中药二厂生产，批号为900616的双黄连粉针剂。
The possible reasons for Shuang Huanglian's departure from Shanhaiguan were partly due to the fact that production problems were solved - in the early 1990s, two key product batches appeared in several papers: Shuanghuanglian Oral Liquid No. 890324 by Heilongjiang Pharmaceutical Laboratory, and Shuanghuanglian Powder No. 900616, produced by Harbin Chinese medicine factory No. 2.
而就是这个粉针剂，还带来了另一方面的原因：在1992年上海某医院的论文中[7]，提到一个很可能让双黄连走向全国的事件：第一届双黄连粉针剂学术研讨会。
And that powder brings another reason: At a Shanghai hospital in 1992, a paper by AT & # 39; 7 & # 93; & # 39; & # 39; & # 39; & # 39; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; &
朱良争等人的论文《双黄连治疗呼吸道感染》[7]截图这可能就是早期医药营销或“学术推广”的一个鲜明案例。
Zhu Liangzheng et al. 's paper Shuanghuanglian for Respiratory Tract Infection & # 91; & # 39; & # 39; & # 39; & # 39; & # 39; & # 45; & # 45; This may be a striking example of early medical marketing or "academic promotion."
这本论文集，今天甚至还可以在旧书网站上以26元的白菜价买来一本。
This collection of essays can even be bought today for 26 yuan in Chinese on the site of old books.
为什么是1992年？哈药集团在1991年重组，哈药控股进入资本市场，哈尔滨中药二厂，正是1988年哈药集团成立时并入哈药集团的药厂之一，在1991年改制后，又成为哈药控股的分公司。
Why was it in 1992? In 1991, the reorganization of the pharmaceutical group, Haji Holdings into the capital market, Harbin herbal medicine factory, was founded in 1988 when the pharmaceutical group was integrated into one of the pharmaceutical companies, in 1991 after the restructuring, and became a subsidiary of HARDIN Holdings.
随后，哈药控股成为中国第一家上市的医药企业。
Subsequently, Hutchison became the first Chinese listed pharmaceutical company.
此后，双黄连就开始大步流星走向全国。
Since then, Shuang Huanglian began to stride toward the country.
双黄连注射剂创造过很多个第一，第一个能供静脉使用的纯中药粉针剂，也是中国第一家上市药企的重要产品。
Shuanghuanglian injection has created many first, the first pure Chinese medicine injection can be used intravenously, is also the first listed pharmaceutical enterprises in China's important products.
但市场无情，出了山海关的双黄连，也要经历市场的考验了。
But the market ruthless, out of Shanhaiguan Shuang Huanglian, but also going through the market test.
河南：学习者、挖角者和竞争者双黄连发迹于东北地区，也顺理成章地成为该地药企的重点明星产品。
Henan: Learners, poachers and competitors Shuangwanglian in the Northeast region, also naturally become the key star products of pharmaceutical enterprises there.
到目前为止，国家药监局（NMPA）批准的85个国药准字号双黄连制剂中，东北地区拿下36个，而黑龙江一省独占32个。
So far, the State Administration of Pharmaceutical Supervision (NMPA) has approved 85 Chinese medicine Xianghuanglian preparations, 36 in the Northeast region and 32 in Heilongjiang Province alone.
双黄连奠定了哈药集团崛起的基础，但其它地区的双黄连生产也在快速跟进，比如河南。
Shuanghuanglian laid the foundation for the rise of pharmaceutical group, but other areas of Shuanghuanglian production is also fast-tracking, such as Henan.
河南地区拿下了9个双黄连制剂的国字号批文，还拥有金银花的道地产区新密。
Henan region has taken nine Shuanghuanglian preparation of the Chinese name approval, but also has honeysuckle of the new production area.
并最终成就了两家以生产双黄连起家的上市药企：郑州的太龙药业和淅川的福森药业。
And finally achieved the production of two listed pharmaceutical enterprises Shuanghuanglian starting up: the Zhengzhou Tailong Pharmaceutical Industry and the Fuxian Pharmaceutical Industry.
很可能是受到1992年哈尔滨中药二厂举办的“第一届双黄连粉针剂学术研讨会”的启发，河南地区纷纷成立双黄连药企。
It was probably inspired by the "First Shuanghuanglian Injection Symposium" held in Harbin in 1992 by the Second Factory of Chinese Medicine, and Shuanghuanglian Pharmaceutical Company was established in Henan Province.
太龙药业（前身为郑州竹林众生）成立于1993年，通过从哈尔滨中药四厂获得双黄连口服液转让权，并挖角其总工程师邢泽田（他也是首个双黄连口服液专利发明人），开始双黄连口服液的生产业务；福森药业（前身为淅川制药）成立于1995年；另一座位于河南开封的药企河南天地药业成立于1997年，除了生产醒脑静注射液，也生产双黄连口服液（如今，上市公司天士力集团持有其60%的股份）。
Founded in 1993, Tai Long Pharmaceutical (formerly Zhengzhou Zhuren) acquired the right to transfer Shuanghuanglian Oral Liquid from Harbin Traditional Chinese Medicine Factory and began producing Shuanghuanglian Oral Liquid from its chief engineer, Xing Ze-tian (he was the first patented Shuanghuanglian Oral Liquid).
B端市场的强劲需求，导致金银花的收购价不断上涨。
Strong demand from the B-end market has led to rising honeysuckle prices.
最难受的是哈药股份，从2016年起，哈药股份在连续三年的年报中，大谈原药材价格过高的问题。
The most afflictive is the Hai drug shares, from 2016 onwards, in the annual report for three consecutive years, talk about the original medicinal materials prices too high.
下图是哈药股份2018年报的原药价格走势，金银花的价格从2016年的80元/公斤，一路涨到2018年180元/公斤以上的高位。
The following chart shows the price trend of the 2018 annual report of HARDES. The price of honeysuckle rose from 80 yuan / kg in 2016 to a high of 180 yuan / kg in 2018.
哈药股份在2018年财报[8]中出示的原药材价格变化趋势，数据来源丨药通网事实上，涨势并未停止，放大灯团队（ID：guokr233）查询药通网数据发现，2020年2月初，最次等的金银花（白花）的收购价也已经高达175元/公斤，而最优质的青花则达到280元/公斤。
The price trend for crude drugs presented at AT & # 91; # 91; 8 & # 93; & # 39; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45
原药材价格连续三年攀升、双黄连口服液销量下滑，导致整个行业都不景气。
The original prices rose for three consecutive years, Shuanghuanglian oral liquid sales decline, resulting in the depression of the entire industry.
哈药股份2017年、2018年的双黄连口服液产量分别同比下降17%和4.71%。
Herbal medicine shares in 2017, 2018 Shuanghuanglian oral liquid production down 17% and 4.71%, respectively.
2020年1月22日，哈药股份发布《哈药股份2019年年度业绩预减公告》[9]称，预期2019年净利润与上年同期减少2.7亿元到3.1亿元，同比减少78%到90%；福森药业2019年半年报显示，其双黄连口服液与注射液营收下滑21%~44%。
On January 22, 2020, Hutchison announced its annual profit forecast for 2019, down 270 million yuan to 310 million yuan from a year earlier, down 78% to 90% from a year earlier, and 21% to 44% lower in Shuang Huanglian Oral Liquid and Injection camp, according to the 2019 semi-annual report.
面对连年上涨的原药价格，药企并非束手待毙。
In the face of years of rising raw drug prices, pharmaceutical companies do not sit idly by.
事实上，双黄连生产商从2015年就试图以“改变处方”的方式自救。
Indeed, Shuangghuang producers have been trying to save themselves by "changing the prescription" since 2015.
在座各位，可能没喝过正宗双黄连从2015年开始，太龙药业、哈药股份就开始向国家药典委员会提交申请，试图将双黄连口服液/胶囊处方中的金银花改为山银花。
All of you may not have drunk authentic Shuanghuanglian Since 2015, Tai Long Pharmaceutical Industry, Hakata shares began to submit an application to the National Pharmacopoeia Commission, in an attempt to change the prescription of Shuanghuanglian Oral Liquid / Capsule into honeysuckle.
药通网显示，产自湖南的山银花价格仅为90~105元/公斤（2020年2月数据），约为金银花价格的一半。
The price of honeysuckle from Hunan province is only 90-105 yuan per kilogram (February 2020), about half the price of honeysuckle, according to the website.
因此，修改处方的直接目的是降低生产成本。
Therefore, the immediate purpose of modifying the prescription is to reduce production costs.
《关于河南太龙药业股份有限公司“双黄连口服液”处方中金银花变更为山银花申请的公示》[10]，来源丨国家药典委员会官网《关于哈尔滨中药四厂有限公司“双黄连胶囊”处方中金银花变更为山银花申请的公示》[11]，来源丨国家药典委员会官网但金银花本来就是双黄连的主要成分，修改处方之后，双黄连还是双黄连吗？事实上，山银花与金银花之争由来已久。
Notice of the change of honeysuckle to honeysuckle in the prescription of "Shuanghuanglian Oral Liquid" by Henan Tai Long Pharmaceutical Co. Ltd. & # 160; & # 91; & # 39; & # 39; & # 39; & # 39; & # 39; & # 39; & # 39; & # 39; & # 39; & # 39;
2014年8月12日，湖南纪委官员陆群发微博，质疑国家药典委把主产自湖南的“南方金银花”更名为“山银花”的举动，引发大规模网络争论。
On 12 August 2014, Lu Qunfa, an official of Hunan disciplinary committee, challenged the change of the name of "honeysuckle" from Hunan province to "honeysuckle" by the National Pharmacopoeia Commission, sparking a large-scale online debate.
但这场争论并没有给湖南面子。
But the argument did not save Hunan face.
根据《中华人民共和国药典》（2015年版一部）的规定，金银花（LONICERAE JAPONICAE FLOS）的药源，依然只有一个：忍冬科忍冬（Lonicera japonica Thunb.）的干燥花蕾或初开的花[12]。
LonICERA JAPONICAE FLOS is still the only source of medicine under the Chinese Pharmacopoeia (2015 edition): dried buds or buds of Lonicera japonica Thunb. (Lonicera japonica Thunb.) or at least & # 91; 12 & # 93;
2015版药典一部依然将山银花（LONICERAE FLOS）单列，其来源多达4个：忍冬科植物灰链毛忍冬（Lonicera macranthoides Hand. -Mazz.）、红腺忍冬（Lonicera hypoglauca Miq.）、华南忍冬（Lonicera confusa DC.）或黄褐毛忍冬（Lonicera fulvotomentosa Hsu et S.C.Cheng）的干燥花蕾或带初开的花[13]。
A 2015 edition still lists LonICERAE FLOS separately from as many as four sources: Lonicera macranthoides Hand.-Mazz., red honeysuckle (Lonicera hypoglauca Miq.), Lonicera fulvotomentosa Hsu et S.C. Cheng (Lonicera fulvotomentosa Hsu et S.C. Cheng).
根据2015版国家药典一部的规定，无论双黄连口服液[14]还是双黄连胶囊[15]，用的都是金银花，而非山银花。
At the request of the 2015 edition of the National Pharmacopoeia, regardless of whether Shuanghuanglian orally & # 91; 14; 14; or Shuanghuanglian capsules or & # 91; 15; 15; & # 93; & # 39; & # 45; with honeysuckle instead of honeysuckle.
不过除了生产双黄连的药企，还有九芝堂、华润三九（黄石）等其它药企的处方更改申请。
However, in addition to producing Shuanghuanglian pharmaceutical enterprises, there are also Jiuzhitang, China Resources 39 (Huang Shi) and other pharmaceutical companies prescription changes applications.
目前太龙、哈药集团官网的双黄连说明书依然使用的是金银花。
At present, Tai Long, the official website of the pharmaceutical group Shuanghuanglian is still using honeysuckle.
如果新版药典收录了修改后的处方，这些药企就可以名正言顺地改用山银花生产双黄连了。
If the new edition of the Pharmacopoeia includes a revised prescription, these companies could legitimately switch to honeysuckle instead.
但事实上，潜规则依然存在。
But, in fact, the hidden rules remain.
根据我国药典规定，衡量金银花质量的标志物是绿原酸。
According to the Chinese Pharmacopoeia, the marker of honeysuckle quality is chlorogenic acid.
但金银花（即忍冬）藤与叶中绿原酸的含量，反而比入药的花蕾更高，因此不少药厂甚至放弃昂贵的金银花，直接使用忍冬藤、叶入药。
But honeysuckle (or honeysuckle) vines and leaves contain higher levels of chlorogenic acid than medicinal buds, so many pharmaceutical companies even give up expensive honeysuckle and use honeysuckle directly as medicine.
从绿原酸含量检测来说，这个操作也挑不出毛病。
From the content of chlorogenic acid detection, this operation can not pick fault.
无论是换用山银花还是忍冬藤叶，都意味着，你可能并不容易喝到正宗的双黄连。
Whether you switch to honeysuckle or honeysuckle, it means you may not be able to drink authentic Couple Leaf easily.
泡沫还能吹多久？颇耐人玩味的是，就在2月3日涨停当天，太龙药业即抛出《关于股东集中竞价减持股份计划公告》[16]，宣布公司第二大股东通过集中竞价交易的方式，减持其持有公司股份比例不超过公司总股本的 1.05%。
Interestingly, just before trading on February 3, the company announced that its second-largest shareholder had reduced its stake in the company by no more than 1.05% of the company's total equity by means of a centralized bidding exercise.
尽管太龙药业也通过《股票交易异常波动公告》[17]提示投资者注意减持带来的风险，但A股市场似乎对这种股东逢高卖出的行为不以为意，减持公告次日上午，太龙药业再次涨停。
The A-share market appeared unimpressed by the stockholders' sell-off, and the morning after the announcement, Tai Long stopped trading again, despite having been alerted to the risks associated with the stock-trading anomaly.
哈药股份同样再次涨停。
Ha medicine shares also rose and fell again.
2月4日，哈药股份动态市盈率达到惊人的2168.65倍。
On February 4, the dynamic price / earnings ratio of Haidong shares reached a staggering 2168.65 times.
但身在港股的福森药业，截至2月4日收盘，股价下跌12.72%。
But shares in Hong Kong-based Pharmacist Co. ended February 4 down 12.72%.
双黄连生于战争年代，而长于东北，而后在全国各地开花结果。
Shuanghuanglian was born in the war years and grew longer in the Northeast, and then bloomed all over the country.
但原药价格持续走高，换药之后是否能说服患者与市场，依然存疑。
However, the price of raw drugs continues to rise, after changing whether patients and the market can be persuaded, remains doubtful.
迄今为止，还无证据表明双黄连对新冠肺炎有确切临床疗效，A股市场置事实于不顾，利用人们的恐慌心理，持续追高双黄连概念股，无异于继续拱高空中楼阁，吹大泡沫。
So far, there is no evidence that Shuanghuanglian to the new crown pneumonia, the A-share market in spite of the facts, taking advantage of people's panic, continue to pursue the concept of Shuanghuanglian stock, is tantamount to continue to high castle in the air, blowing bubble.
当狂热的趋利心态控制人们的头脑时，再高明的医术，再清醒的科普都将无济于事。
No amount of skill, no amount of sobriety, no amount of science will help when the craze for profit dominates people's minds.
References：[1] 孙效珍,解建设,解鲁豫.双黄连的药理与临床应用.黑龙江医药.2006, 19(1)[2] 我省召开中草药经验交流现场会.黑龙江医药.1976.4[3] 佟奎明,周昆,王德全,李钊.双黄连口服液抗呼吸道合胞病毒的实验研究.1991.1[4] 莫红缨,赖克方,江永南,谢建屏,钟南山.双黄连及其拆方抗呼吸道合胞病毒作用的药效学研究.中国中医基础医学杂志.2005.03[5] 莫红缨,赖克方,江永南,谢建屏,谭亚夏,钟南山.双黄连对呼吸道合胞病毒感染的气道上皮细胞炎症因子释放的影响.广州医学院学报 2005.02[6] 毛刃.双黄连注射液静脉滴注过敏反应1例报告.黑龙江医药.1991.03[7] 朱良争,顾仁樾.双黄连治疗呼吸道感染.新药与临床.1996.06[8] 哈药集团股份有限公司 2018 年年度报告 http://file.finance.sina.com.cn/211.154.219.97:9494/MRGG/CNSESH_STOCK/2019/2019-3/2019-03-16/5086963.PDF[9] 哈药股份2019年年度业绩预减公告 http://data.eastmoney.com/notices/detail/600664/AN202001211374426997,JWU1JTkzJTg4JWU4JThkJWFmJWU4JTgyJWExJWU0JWJiJWJk.html[10] 国家药典委员会：关于河南太龙药业股份有限公司“双黄连口服液”处方中金银花变更为山银花申请的公示 http://www.chp.org.cn/view/ff8080814d41ff59014dbd60bc6a38ea?a=BZZY[11] 国家药典委员会：关于哈尔滨中药四厂有限公司“双黄连胶囊”处方中金银花变更为山银花申请的公示 http://www.chp.org.cn/view/ff808081527bfe27015282a68898086e?a=BZZY[12] 国家药典委员会.中国药典2015年版一部.中国医药科技出版社.2015.6.221页[13] 国家药典委员会.中国药典2015年版一部.中国医药科技出版社.2015.6.30页[14] 国家药典委员会.中国药典2015年版一部.中国医药科技出版社.2015.6.735页[15] 国家药典委员会.中国药典2015年版一部.中国医药科技出版社.2015.6.738页[16] 河南太龙药业股份有限公司关于股东集中竞价减持股份计划公告 http://pdf.dfcfw.com/pdf/H2_AN202002031374730460_1.pdf[17] 河南太龙药业股份有限公司股票交易异常波动公告 http://pdf.dfcfw.com/pdf/H2_AN202002031374730458_1.pdf- 我们的文章，也许你会感兴趣 -《改写历史的养鼠人》《14天锁定新型肺炎元凶背后，是14年的技术竞赛》《国民神药“醒脑静”》《中国商人的失忆解药》- 详细了解“放大灯”及招聘信息，请点这里 -《“哙，亮起来了！”》。
... > http: / / www.chp.org.cn / views / ff808081527bf.com / pdf / H2AN202002031374730460 _ 1.pdf / H2AN202002031374730460 _ 1.pdf / H2AN202002031374730460.
发送到看一看 。
Send it to see.
双黄连：“肺炎神药”的生意经与隐秘往事。
Shuang Huanglian: The Business History and Secret History of "Pneumonia".
查看更多相关内容。
See more for more information.
查看更多相关内容。
See more for more information.
以上推荐为优质及原创文章。
Above recommendations for quality and original articles.
长按识别前往小程序。
Long press identify to go to the applet.
var _ori_article_type = "金融财经";。
var _ ori _ article _ type = & quot; Financial & Finance & quot;;
var nickname = "放大灯";。
Var nickname = & quot; & quot; & quot; & quot; & quot;
var msg_title = "双黄连：“肺炎神药”的生意经与隐秘往事";。
var msg _ title = & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot;
var msg_desc = "市场疯狂追捧双黄连，到底是谁病了？";。
Var msg _ desc = & quot; & quot; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & quot; & quot; & quot; & quot; & quot;
title: '改写历史的养鼠人',。
Rat & apos; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot;.
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
title: '改写历史的养鼠人',。
Rat & apos; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot;.
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
title: '14天锁定新型肺炎元凶背后，是14年的技术竞赛',。
IT IS 14 years of technology competition and behind its 14-day lock on the cause of its new pneumonia.
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
title: '14天锁定新型肺炎元凶背后，是14年的技术竞赛',。
IT IS 14 years of technology competition and behind its 14-day lock on the cause of its new pneumonia.
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
title: '国民神药“醒脑静”',。
& quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot;.
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
title: '国民神药“醒脑静”',。
& quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot;.
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
title: '中国商人的失忆解药丨放大灯',。
Chinese businessmen's amnesia antidote to AT & amp; apos;
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
title: '中国商人的失忆解药丨放大灯',。
Chinese businessmen's amnesia antidote to AT & amp; apos;
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
title: '“哙，亮起来了！”',。
"Kuai, Kuai, has emerged!" & amp; & # 45; & apos; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot;
subject_name: '放大灯',。
Subject _ name: & apos; & quot; & quot; & apos; & quot; & quot; & quot; & apos;.
var title ="放大灯";。
Var title = & quot; & quot; & quot; & quot; & quot;
